Supplementary Table III. Adverse events during baricitinib tapering

Types and frequencies of adverse events recorded during stepwise baricitinib tapering. Data are presented as n/N (%). Events are not mutually exclusive; patients with more than 1 recorded event may appear in multiple rows. Most recorded adverse events were mild, and no event led to adverse event–related baricitinib interruption, discontinuation, or change in the tapering plan.